CY1122374T1 - Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων - Google Patents
Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειωνInfo
- Publication number
- CY1122374T1 CY1122374T1 CY20191101195T CY191101195T CY1122374T1 CY 1122374 T1 CY1122374 T1 CY 1122374T1 CY 20191101195 T CY20191101195 T CY 20191101195T CY 191101195 T CY191101195 T CY 191101195T CY 1122374 T1 CY1122374 T1 CY 1122374T1
- Authority
- CY
- Cyprus
- Prior art keywords
- biotin
- neuropathies
- demyelinotic
- therapeutic treatment
- treatment
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 4
- 229960002685 biotin Drugs 0.000 title abstract 2
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 239000011616 biotin Substances 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000008795 neuromyelitis optica Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Farming Of Fish And Shellfish (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122374T1 true CY1122374T1 (el) | 2021-01-27 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101195T CY1122374T1 (el) | 2015-03-26 | 2019-11-13 | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (enExample) |
| EP (2) | EP3072513A1 (enExample) |
| JP (1) | JP6752874B2 (enExample) |
| KR (1) | KR20170131543A (enExample) |
| CN (2) | CN111973592A (enExample) |
| AU (1) | AU2016238759B2 (enExample) |
| BR (1) | BR112017020408A2 (enExample) |
| CA (1) | CA2980660A1 (enExample) |
| CY (1) | CY1122374T1 (enExample) |
| DK (1) | DK3273957T3 (enExample) |
| EA (1) | EA034394B1 (enExample) |
| ES (1) | ES2748354T3 (enExample) |
| HR (1) | HRP20191491T1 (enExample) |
| HU (1) | HUE046116T2 (enExample) |
| IL (1) | IL254619B (enExample) |
| LT (1) | LT3273957T (enExample) |
| MA (1) | MA41809B1 (enExample) |
| ME (1) | ME03567B (enExample) |
| PL (1) | PL3273957T3 (enExample) |
| PT (1) | PT3273957T (enExample) |
| RS (1) | RS59149B1 (enExample) |
| SI (1) | SI3273957T1 (enExample) |
| SM (1) | SMT201900548T1 (enExample) |
| WO (1) | WO2016151132A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| US12458607B2 (en) * | 2018-12-11 | 2025-11-04 | Myospots Australia Pty Ltd | Adhesive pad |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| EP4225327A4 (en) * | 2020-10-09 | 2024-10-16 | TX Medic AB | TREATMENT OF MUSCLE ATROPHY WITH DEXTRAN SULFATE |
| WO2023081458A1 (en) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systems and methods for diagnosis and/or treating demyelinating neuropathy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| PL377612A1 (pl) | 2002-09-27 | 2006-02-06 | Biogen Idec Ma Inc. | Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| US10654916B2 (en) * | 2011-04-21 | 2020-05-19 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
| WO2013010015A2 (en) * | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| US9789092B2 (en) | 2013-04-29 | 2017-10-17 | Assistance Publique—Hopitaux de Paris | Biotin for use in treating X-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en not_active Ceased
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1123417T1 (el) | Παραγωγα τετρα�δροϊσοκινολινης | |
| JOP20190194B1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
| CY1121182T1 (el) | Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| IL285771A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| MX377273B (es) | Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1). | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. |